Kelly Fitzgerald

GU oncology at UCSF | MSKCC fellowship alum | cancer immunology and metabolism | tweets are mine

[Katy Beckermann @katy_beckermann]

Sunrise run at #IKCS25 with amazing colleagues ✨ No better way to come together, recharge, and stay grounded in why we do this work. Grateful for this community and for every step we take to push kidney cancer care forward. #GUonc #KidneyCancer

[Kelly Fitzgerald @KellyNFitz]

Great talk by @MdArpita #ucsf at #IKCSNA25 succinctly summarizing options in the challenging setting of IO resistance in RCC. We are looking ahead to earlier implementation of HIF2a blockade and earlier access to trials for our patients. @KidneyCancer

[Cancer Discovery @CD_AACR]

From the May issue: 'Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in RCC https://t.co/yY51Qjxhkk
By Miya Hugaboom, @lena__wirth, Kelly Street, @nruthen16, Michael Atkins, Catherine Wu, @BraunMDPhD

[Juan C Osorio MD @juanosoriomd]

Interested in myeloid cell anti-tumor immunity? I’ll be presenting at @theNCI Rising Scholars Seminar Series on 17 Apr our work on Fc-optimized CD40 Agonistic Antibody and TLS formation and induction of Systemic Antitumor Immunity https://t.co/9MloD5XTI6

[Andy Hahn @OncHahn]

(1/3) Check out our multicenter, IIT of sitravatinib + nivolumab after ICI in patients with metastatic ccRCC https://t.co/eKtW766nkJ This trial was terminated early (14 of 88 planned) but built upon our group’s experience with sitravatinib led by @PavlosMsaouel

[Kidney Cancer @KidneyCancer]

Federal #kidneycancer research funding drops from $50 million to ZERO after 57% cut to CDMRP. All but 12 of the 35 disease research programs saw funding eliminated for 2025, including the Kidney Cancer Research Program. More about the impact on our blog. https://t.co/MUvUuMJiIV

[Kidney Cancer @KidneyCancer]

UPDATE 3/12: Last night the House voted to cut 57% of federally funded medical and cancer research through the CDMRP. Vote moves on to Senate and, if passed, to be signed into law by the President.

More details: https://t.co/N2E4n1pfTd

[Kelly Fitzgerald @KellyNFitz]

@ZiadBakouny @EdReznik @motzermd @MSKCancerCenter @MSK_DeptOfMed @arihakimi @MVossMD @KotechaMD Awesome!!

[Katy Beckermann @katy_beckermann]

Happening Today **Kidney Cancer Association's 2024 Virtual Patient Summit** for education and support! 🎗️🧠

📅 Learn more and register here: [https://t.co/Cpu3IFRBJN]

#KidneyCancer #PatientEducation @KidneyCancer @may_alley @DrRanaMcKay @KidneyCancerDoc @KellyNFitz

[Kelly Fitzgerald @KellyNFitz]

@BraunMDPhD eloquently summarizes the principles driving innovation in immunotherapy at #KCRS24

[Toni Choueiri, MD @DrChoueiri]

Immunotherapy in 1 slide courtesy of @BraunMDPhD during #KCRS24

@kidneycan

[Jim Smithy @jsmithymd]

@MSKCancerCenter cofellows taking in the view at #asco24 @KellyNFitz @Yonit_Lavin @SherryShenMD

[Kelly Fitzgerald @KellyNFitz]

Interesting to consider a ‘very favorable risk’ subgroup of ccRCC patients and the role of VEGFR targeted therapies here. How will HIF2a blockade perform in these patients?

[Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang]

#MartinZarba @DrDanielHeng @UCalgaryMed with IMDC very/favorable risk #kidneycancer — all regimens w excellent survival. Ipi-nivo doublet falls short in very favorable risk RCC. @ASCO #ASCO24 @OncoAlert

[Kelly Fitzgerald @KellyNFitz]

Congrats to @dsahil320 Sahil Doshi for this retrospective analysis of outcomes on first-line therapy in >100 patients with #chromophobe rcc. Looking forward to seeing longer term follow-up in patients in the doublet cohorts. @MVossMD @NazliDizman @OncHahn @dreaknezevic

[Pavlos Msaouel @PavlosMsaouel]

Thoroughly enjoyed reading this overview of selected molecularly defined aggressive #kidneycancer subtypes by @Unclassified1 👉 https://t.co/HPyCegndkQ #RenalMedullaryCarcinoma #RareCancers #HLRCC #endRMC @KidneyCancer @RmcAlliance @RMCAwareness @renalmedullary @RareCancerRF

[Jonathan Rosenberg MD @DrRosenbergMSK]

Big news for bladder cancer in US!
“On December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer (la/mUC).”

[Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang]

Great news for our patients w #kidneycancer!! Belzutifan now approved in refractory disease based on #LITESPARK005 data from @AlbigesL et al. @kcCURE @KidneyCancer @kidneycan

[Javid Moslehi @CardioOncology]

Exited to have Dr. Kelly Fitzgerald @KellyNFitz speak at UCSF #CardioOnc conference this THU. Discussion of RCC/kidney cancer & CardioOnc. Focus on VEGF/HIF inhibitors and immune checkpoints! @UCSFCardiology @UCSFCancer @baik_alan @MandarArasMD

[Kelly Fitzgerald @KellyNFitz]

Happy to share our findings at #IKCSNA23! In our single-institution retrospective cohort, no evidence of superiority of either IO/IO or TKI/IO in #kidneycancer 1L tx with regard to PFS2, including in groups w/ sarcomatoid features, BAP1 mutation, or deep RECIST response.

[Bradley McGregor @BradMcG04]

Zanzalitinib with activity in refractory RCC with manageable safety profile even in those patients who had previously received cabozantinib @montypal @DrChoueiri @KidneyCancer

[Kelly Fitzgerald @KellyNFitz]

@ReneeSaliby @TJammihal @Chrislabaki1 @DrChoueiri @ShuklaSachet @BraunMDPhD @myESMO @OncoAlert @DanaFarberNews @kidneycan @urotoday @Uromigos @OncLive @DanaFarber_GU @LabSignoretti @DrDanielHeng @Nourhanelahmar @TalalZarif1 Congrats Renee!!